Showing results (1-10 of 10) with videos related to
Sort By:
Pageof 1
Chemical Society Reviews|January 17, 2008
Fluorine in medicinal chemistrySophie Purser, Peter R Moore, Steve Swallow, et al.Journal of Labelled Compounds & Radiopharmaceuticals|December 16, 2020
The impact of radiochemistry in drug projects: The use of C-14 label in the AZD8529, AZD7325, and AZD6280 projectsLee Kingston, Chungang Gu, Jian Guo, et al.Chemical Research in Toxicology|September 10, 2015
Aortic Binding of AZD5248: Mechanistic Insight and Reactivity Assays To Support Lead OptimzationRyan A Bragg, Simon Brocklehurst, Frida Gustafsson, et al.Organic Letters|November 20, 2013
Novel and versatile synthesis of disubstituted 1,2-dihydro-1,2,4-triazol-3-onesMark A Graham, Paul A Bethel, Jonathan Burgess, et al.Journal of Medicinal Chemistry|October 4, 2016
Discovery of Second Generation Reversible Covalent DPP1 Inhibitors Leading to an Oxazepane Amidoacetonitrile Based Clinical Candidate (AZD7986)Kevin Doyle, Hans Lönn, Helena Käck, et al.Bioorganic & Medicinal Chemistry Letters|May 22, 2012
The discovery of N-cyclopropyl-4-methyl-3-[6-(4-methylpiperazin-1-yl)-4-oxoquinazolin-3(4H)-yl]benzamide (AZD6703), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseasesDearg S Brown, John G Cumming, Paul Bethel, et al.Chemical Research in Toxicology|June 1, 2012
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugsRichard A Thompson, Emre M Isin, Yan Li, et al.Bioorganic & Medicinal Chemistry Letters|August 20, 2011
Strategies to improve in vivo toxicology outcomes for basic candidate drug moleculesTim Luker, Lilian Alcaraz, Kamaldeep K Chohan, et al.Journal of Medicinal Chemistry|April 5, 2017
Structure-Guided Discovery of Potent and Selective Inhibitors of ERK1/2 from a Modestly Active and Promiscuous Chemical Start PointRichard A Ward, Paul Bethel, Calum Cook, et al.Journal of Medicinal Chemistry|November 12, 2019
Discovery of a Potent and Selective Oral Inhibitor of ERK1/2 (AZD0364) That Is Efficacious in Both Monotherapy and Combination Therapy in Models of Nonsmall Cell Lung Cancer (NSCLC)Richard A Ward, Mark J Anderton, Paul Bethel, et al.Pageof 1